Todos MedicalLtd. (OTCMKTS:TOMDF) was up 3% after the medical diagnosis, and the associated solutions firm announced that 3CL Pharma Ltd., its majority-owned affiliate, had received a waiver from Institutional Review Board (IRB) to commence a market research survey to collect and assess consumer feedback about the use of Tollovid Daily and Tollovid, its 3CL protease antagonist immune support dietary supplements in the Long COVID and COVID paths.
On Wednesday, TOMDF stock gained 3.15% to $0.0131 with 4.55 million shares, compared to its average volume of 6.42 million shares. The stock moved within a range of $0.0125 – 0.0133 after opening trade at $0.0128.
It is important to note that Tollovid Daily and Tollovid have not been approved to diagnose, prevent, treat or cure any illness, including Long COVID and/or COVID. Customers will be contacted electronically in the coming weeks to complete surveys created by the company’s physician-scientist teams to help the company determine its next actions.
Todos Medical is an in vitro screening firm specializing in the research of innovative blood testing for the early diagnosis of cancer and neurological diseases like Alzheimer’s disease and the distribution of COVID-19 screening products. So in the coming weeks, TOMDF is worth watching.
TOMDF stock is trading below the 20-Day and 50-Day Moving averages of $0.0162 and $0.0237 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0389.